InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,967.23
(
-0.88%
)
US TECH 100
16,556.80
(
-2.24%
)
Dow Jones
37,986.40
(
0.56%
)
Brent Oil
86.63
(
0.00%
)
Bitcoin
63,820.55
(
0.01%
)
Post# of 76
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

bell345

Send PM Follow Ignore
Followers 46
Posts 5334
Boards Moderated 1
Alias Born 05/04/2005

bell345

Re: None

Tuesday, 11/12/2013 6:43:03 AM

Tuesday, November 12, 2013 6:43:03 AM

Post# of 76
Jason Kolbert, Sr. Research Analyst at the Maxim Group, who started DNDN with a sell on DNDN, now has a buy with a 10.00 target.

They will do around 300 to 400 mil in revs in USA alone, 50% in margins you'll get 200 mil in free cash flow. Three to five times suggest a take out value of 1 to 1.5 billion. A company THAT ALREADY HAS the infrastructure for prostate cancer like Astellas Pharma, Inc. (ALPMY) or JNJ, would dovetail in existing products.

All posts are In my opinion, and are not meant to harm or defame anyone, please do your own DD. Please click on my Favorite Links, Journey to the Edge of the Universe & tell me what you think.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up